A.R.T. Advisors’s Heron Therapeutics HRTX Stock Holding History

A.R.T. Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-83,187	Closed	-$1.96M	–	479
2019 Q4	$1.96M	Sell	83,187 -43,291	-34%	-$958K	0.1%	302
2019 Q3	$2.34M	Buy	+126,478	New	+$2.33M	0.12%	232
2018 Q3	–	Sell	-31,534	Closed	-$1.23M	–	1524
2018 Q2	$1.23M	Buy	+31,534	New	+$1M	0.05%	540
2018 Q1	–	Sell	-50,300	Closed	-$910K	–	1612
2017 Q4	$910K	Buy	+50,300	New	+$820K	0.04%	663
2015 Q4	–	Sell	-71,138	Closed	-$1.74M	–	1567
2015 Q3	$1.74M	Buy	+71,138	New	+$2.37M	0.06%	422
2015 Q2	–	Sell	-27,635	Closed	-$402K	–	1570
2015 Q1	$402K	Buy	+27,635	New	+$312K	0.01%	996

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

A.R.T. Advisors's HRTX Position: Q1 2020 in Review

A.R.T. Advisors sold out of Heron Therapeutics (HRTX) in Q1 2020, closing a stake of 83,187 shares — an estimated $1.96M sold.

A.R.T. Advisors first reported a position in HRTX in Q1 2015 and held it in 6 quarters. The position peaked at $2.34M in Q3 2019. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

A.R.T. Advisors reported no remaining Heron Therapeutics position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 83,187 Heron Therapeutics shares in Q1 2020, an estimated $1.96M.
A.R.T. Advisors first reported a position in Heron Therapeutics in Q1 2015 and held it in 6 quarters.
A.R.T. Advisors's Heron Therapeutics position peaked at $2.34M in Q3 2019.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.